Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) has been given an average rating of “Hold” by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $62.8333.
Several analysts recently commented on the stock. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th.
Check Out Our Latest Stock Analysis on Supernus Pharmaceuticals
Trending Headlines about Supernus Pharmaceuticals
- Positive Sentiment: Merger creates scale and potential synergies: Supernus and Indivior agreed to combine in a tax-free, all-stock transaction expected to create a CNS-focused company with approximately $2.2 billion in annual revenue, 11 commercial medicines and $125 million in annual cost synergies. Supernus CEO Jack Khattar will lead the combined company, which is expected to retain the SUPN ticker. The deal is targeted to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals. Merger announcement
- Positive Sentiment: Revenue growth and guidance increase: Second-quarter revenue rose 32% year over year to $219.1 million, driven by growth products including Qelbree, GOCOVRI, ONAPGO and ZURZUVAE collaboration revenue. Supernus raised 2026 revenue guidance to $860 million-$890 million and adjusted operating earnings guidance to $150 million-$180 million. ONAPGO sales reached $13.5 million, while ZURZUVAE collaboration revenue totaled $35.4 million. Second-quarter results
- Neutral Sentiment: Deal exchange terms: Supernus shareholders are slated to receive 1.5401 Indivior shares for each SUPN share and would own approximately 43.5% of the combined company. Indivior shareholders would receive a $1 billion special dividend funded partly by $650 million of new debt, creating financing and execution considerations.
- Negative Sentiment: GAAP profitability weakened: Supernus reported a second-quarter net loss of $58.4 million, or $1.01 per share, compared with net income of $22.5 million a year earlier. Results included a $54.9 million non-cash impairment charge tied to APOKYN, while legacy Trokendi XR, Oxtellar XR and APOKYN sales declined.
- Negative Sentiment: Shareholder-law-firm investigations: Several investor-rights firms announced investigations into whether Supernus directors obtained a fair price and fulfilled their fiduciary duties in the Indivior transaction. These announcements do not establish wrongdoing but could add legal costs, delay risk and uncertainty around the merger. Shareholder investigation
Supernus Pharmaceuticals Stock Performance
Shares of NASDAQ SUPN opened at $46.00 on Thursday. The firm has a market capitalization of $2.67 billion, a P/E ratio of -90.20, a PEG ratio of 0.95 and a beta of 0.56. Supernus Pharmaceuticals has a one year low of $35.51 and a one year high of $59.68. The company’s fifty day moving average is $46.22 and its two-hundred day moving average is $49.05.
Institutional Trading of Supernus Pharmaceuticals
Large investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its position in shares of Supernus Pharmaceuticals by 68.1% in the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after buying an additional 4,729 shares in the last quarter. AQR Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 35.2% during the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after acquiring an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares during the last quarter. Millennium Management LLC raised its position in Supernus Pharmaceuticals by 370.5% during the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC lifted its stake in Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after buying an additional 6,619 shares in the last quarter.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Featured Stories
- Five stocks we like better than Supernus Pharmaceuticals
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
